These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1069 related articles for article (PubMed ID: 33796113)

  • 61. Interleukin-33 as a Biomarker Affecting Intrathecal Synthesis of Immunoglobulin in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Wang M; Xia D; Sun L; Bi J; Xie K; Wang P
    Eur Neurol; 2023; 86(4):256-262. PubMed ID: 37100033
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
    Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
    BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion.
    Gawde S; Siebert N; Ruprecht K; Kumar G; Ko RM; Massey K; Guthridge JM; Mao-Draayer Y; Schindler P; Hastermann M; Pardo G; Paul F; Axtell RC
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200268. PubMed ID: 38885457
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.
    Li EC; Zheng Y; Cai MT; Lai QL; Fang GL; Du BQ; Shen CH; Zhang YX; Wu LJ; Ding MP
    Epilepsia; 2022 Sep; 63(9):2173-2191. PubMed ID: 35652436
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder.
    Carta S; Dinoto A; Capobianco M; Valentino P; Montarolo F; Sala A; Reindl M; Lo Re M; Chiodega V; Branger P; Audoin B; Aboab J; Papeix C; Collongues N; Kerschen P; Zephir H; Créange A; Bourre B; Schanda K; Flanagan EP; Redenbaugh V; Villacieros-Álvarez J; Arrambide G; Cobo-Calvo A; Ferrari S; Marignier R; Mariotto S
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):e200188. PubMed ID: 38134369
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Cacciaguerra L; Abdel-Mannan O; Champsas D; Mankad K; Krecke KN; Chen JJ; Syc-Mazurek SB; Redenbaugh V; Lopez-Chiriboga AS; Valencia-Sanchez C; Hemingway C; Tillema JM; Ciccarelli O; Pittock SJ; Hacohen Y; Flanagan EP
    Neurology; 2024 May; 102(10):e209303. PubMed ID: 38710000
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Brier MR; Wu GF; Chahin S; Cross AH; Naismith RT
    Mult Scler; 2022 Jan; 28(1):49-60. PubMed ID: 33870786
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bilateral parafalcine cortical and leptomeningeal impairment in MOG antibody disease and AQP4 neuromyelitis optica.
    Jiang W; Sun X; Huang H; Sun H; Zhang S; He M; Yu X; Huang D; Wu L
    J Neuroimmunol; 2022 Aug; 369():577898. PubMed ID: 35717737
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A study of referral bias in NMOSD and MOGAD cohorts.
    Leal Rato M; Chen B; Francis A; Messina S; Miron M; Sharawakanda Y; O'Sullivan E; Cooper S; Fisniku L; Halfpenny C; Martin R; Hobart J; Rashid W; Hemingway C; Williams V; Hacohen Y; Dobson R; Ramdas S; Leite MI; Palace J; Geraldes R
    Mult Scler Relat Disord; 2024 May; 85():105553. PubMed ID: 38552551
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
    Luo X; Li H; Xia W; Quan C; ZhangBao J; Tan H; Wang N; Bao Y; Geng D; Li Y; Yang L
    Eur Radiol; 2024 Jul; 34(7):4364-4375. PubMed ID: 38127076
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up.
    Petzold A; Woodhall M; Khaleeli Z; Tobin WO; Pittock SJ; Weinshenker BG; Vincent A; Waters P; Plant GT
    J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1021-1026. PubMed ID: 31118222
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.
    Vardakas I; Dorst J; Huss A; Mayer B; Fangerau T; Taranu D; Tumani H; Senel M
    Eur J Neurol; 2024 Aug; 31(8):e16323. PubMed ID: 38700322
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
    Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
    Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
    Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD.
    Wang L; Xia R; Li X; Shan J; Wang S
    Front Immunol; 2023; 14():1293100. PubMed ID: 38259484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.